

Experiment Number: 20209 - 03
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/Wistar Han

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 08/12/2014
 Time Report Requested: 10:27:34
 First Dose M/F: 08/26/08 / 08/26/08
 Lab: SRI

Wistar Han RATS MALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
Disposition Summary				
Animals Initially In Study	60	50	50	60
Early Deaths				
Dosing Accident	1	1		1
Moribund Sacrifice	8	7	10	12
Natural Death	4	7	2	12
Survivors				
Terminal Sacrifice	36	35	38	25
Animals Examined Microscopically	49	50	50	50

ALIMENTARY SYSTEM

Esophagus	(49)	(50)	(50)	(50)
Hyperkeratosis	1 (2%)	1 (2%)		
Inflammation, Acute				1 (2%)
Ulcer				1 (2%)
Muscularis, Degeneration		1 (2%)		
Muscularis, Hemorrhage		1 (2%)		
Periesophageal Tissue, Inflammation, Granulomatous, Chronic	1 (2%)			
Intestine Large, Cecum	(46)	(43)	(49)	(43)
Inflammation, Chronic		1 (2%)		
Intestine Large, Colon	(48)	(45)	(50)	(48)
Inflammation, Chronic		1 (2%)		
Intestine Large, Rectum	(48)	(46)	(49)	(47)
Inflammation, Acute				2 (4%)
Intestine Small, Duodenum	(46)	(45)	(49)	(46)
Inflammation, Acute				1 (2%)
Epithelium, Vacuolization Cytoplasmic	1 (2%)			
Intestine Small, Ileum	(45)	(43)	(49)	(42)
Inflammation, Focal, Chronic Active			1 (2%)	
Peyer's Patch, Hyperplasia			1 (2%)	
Intestine Small, Jejunum	(45)	(44)	(50)	(46)
Ulcer		1 (2%)		
Epithelium, Vacuolization Cytoplasmic	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 03

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Wistar Han

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 08/12/2014

Time Report Requested: 10:27:34

First Dose M/F: 08/26/08 / 08/26/08

Lab: SRI

Wistar Han RATS MALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
Peyer's Patch, Hyperplasia			1 (2%)	
Liver	(49)	(50)	(50)	(50)
Angiectasis			1 (2%)	1 (2%)
Basophilic Focus	8 (16%)	4 (8%)	3 (6%)	7 (14%)
Basophilic Focus, Multiple	8 (16%)	17 (34%)	8 (16%)	4 (8%)
Cholangiofibrosis			1 (2%)	1 (2%)
Clear Cell Focus	1 (2%)	1 (2%)		2 (4%)
Clear Cell Focus, Multiple	38 (78%)	36 (72%)	35 (70%)	27 (54%)
Congestion	4 (8%)	3 (6%)		2 (4%)
Degeneration, Cystic			1 (2%)	1 (2%)
Eosinophilic Focus	3 (6%)	2 (4%)	10 (20%)	7 (14%)
Eosinophilic Focus, Multiple		1 (2%)	2 (4%)	8 (16%)
Fatty Change	32 (65%)	37 (74%)	48 (96%)	48 (96%)
Fibrosis	1 (2%)			1 (2%)
Hematopoietic Cell Proliferation			1 (2%)	
Hemorrhage	2 (4%)		1 (2%)	
Hepatodiaphragmatic Nodule		1 (2%)		1 (2%)
Hyperplasia, Nodular			3 (6%)	
Inflammation, Chronic	1 (2%)	2 (4%)		5 (10%)
Mixed Cell Focus	2 (4%)	2 (4%)		2 (4%)
Mixed Cell Focus, Multiple		1 (2%)	1 (2%)	2 (4%)
Pigmentation			1 (2%)	6 (12%)
Thrombosis	1 (2%)			
Artery, Degeneration			1 (2%)	
Artery, Inflammation, Chronic				1 (2%)
Bile Duct, Cyst				1 (2%)
Bile Duct, Hyperplasia	16 (33%)	17 (34%)	16 (32%)	16 (32%)
Hepatocyte, Hypertrophy	1 (2%)	44 (88%)	50 (100%)	50 (100%)
Hepatocyte, Necrosis	4 (8%)	2 (4%)	1 (2%)	5 (10%)
Oval Cell, Hyperplasia			2 (4%)	3 (6%)
Mesentery	(12)	(6)	(13)	(10)
Hemorrhage	2 (17%)	1 (17%)		1 (10%)
Inflammation, Chronic			1 (8%)	
Fat, Necrosis	9 (75%)	5 (83%)	11 (85%)	9 (90%)
Oral Mucosa	(1)	(0)	(0)	(0)
Pancreas	(46)	(47)	(50)	(49)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 03

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Wistar Han

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 08/12/2014

Time Report Requested: 10:27:34

First Dose M/F: 08/26/08 / 08/26/08

Lab: SRI

Wistar Han RATS MALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
Atrophy	3 (7%)	5 (11%)	7 (14%)	1 (2%)
Basophilic Focus			1 (2%)	
Basophilic Focus, Multiple				1 (2%)
Hyperplasia		1 (2%)	2 (4%)	1 (2%)
Inflammation, Acute		1 (2%)		
Inflammation, Chronic	1 (2%)			
Pigmentation, Hemosiderin	1 (2%)			
Duct, Cyst		1 (2%)		
Duct, Cyst, Multiple			2 (4%)	
Salivary Glands	(46)	(48)	(50)	(50)
Duct, Parotid Gland, Cyst		1 (2%)	2 (4%)	
Duct, Parotid Gland, Inflammation, Acute	1 (2%)	1 (2%)		4 (8%)
Duct, Submandibular Gland, Inflammation, Acute				1 (2%)
Parotid Gland, Atrophy	2 (4%)	2 (4%)	4 (8%)	13 (26%)
Parotid Gland, Basophilic Focus				1 (2%)
Parotid Gland, Hyperplasia, Focal	1 (2%)			
Parotid Gland, Inflammation, Chronic	1 (2%)	1 (2%)	1 (2%)	
Parotid Gland, Vacuolization Cytoplasmic	4 (9%)	4 (8%)	7 (14%)	17 (34%)
Sublingual Gland, Atrophy				1 (2%)
Sublingual Gland, Vacuolization Cytoplasmic				1 (2%)
Submandibular Gland, Inflammation, Acute				1 (2%)
Submandibular Gland, Inflammation, Chronic		1 (2%)		
Submandibular Gland, Vacuolization Cytoplasmic				1 (2%)
Stomach, Forestomach	(49)	(50)	(50)	(50)
Edema		1 (2%)		2 (4%)
Erosion	1 (2%)	1 (2%)		
Hyperkeratosis	9 (18%)	5 (10%)	5 (10%)	17 (34%)
Inflammation, Acute	1 (2%)	2 (4%)	1 (2%)	4 (8%)
Inflammation, Chronic	3 (6%)	1 (2%)	2 (4%)	4 (8%)
Inflammation, Chronic Active	3 (6%)	2 (4%)	2 (4%)	3 (6%)
Ulcer	3 (6%)	1 (2%)	3 (6%)	5 (10%)
Epithelium, Hyperplasia	8 (16%)	6 (12%)	5 (10%)	17 (34%)
Stomach, Glandular	(48)	(46)	(50)	(49)
Cyst			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 03

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Wistar Han

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 08/12/2014

Time Report Requested: 10:27:34

First Dose M/F: 08/26/08 / 08/26/08

Lab: SRI

Wistar Han RATS MALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
Fibrosis		1 (2%)		
Inflammation, Multifocal, Chronic		1 (2%)		
Inflammation, Acute			1 (2%)	2 (4%)
Inflammation, Chronic				1 (2%)
Mineralization	7 (15%)	3 (7%)	5 (10%)	2 (4%)
Tongue	(0)	(1)	(0)	(0)
Infiltration Cellular		1 (100%)		
Tooth	(1)	(0)	(0)	(0)

CARDIOVASCULAR SYSTEM

Blood Vessel	(0)	(2)	(0)	(0)
Angiectasis		1 (50%)		
Heart	(49)	(50)	(50)	(50)
Cardiomyopathy	33 (67%)	32 (64%)	34 (68%)	29 (58%)
Inflammation, Acute				1 (2%)
Necrosis, Multifocal				1 (2%)
Pigmentation, Hemosiderin				1 (2%)
Thrombosis				1 (2%)
Endocardium, Hyperplasia		1 (2%)		
Epicardium, Inflammation, Granulomatous	1 (2%)			
Epicardium, Inflammation, Chronic				1 (2%)
Pericardium, Inflammation, Granulomatous				1 (2%)
Pericardium, Necrosis		1 (2%)		

ENDOCRINE SYSTEM

Adrenal Cortex	(49)	(49)	(50)	(49)
Accessory Adrenal Cortical Nodule				1 (2%)
Angiectasis	13 (27%)	17 (35%)	15 (30%)	18 (37%)
Degeneration, Cystic	1 (2%)			
Hyperplasia, Focal	13 (27%)	10 (20%)	18 (36%)	16 (33%)
Hypertrophy, Focal	9 (18%)	11 (22%)	7 (14%)	8 (16%)
Necrosis, Focal				1 (2%)
Vacuolization Cytoplasmic	12 (24%)	9 (18%)	10 (20%)	17 (35%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 03

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Wistar Han

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 08/12/2014

Time Report Requested: 10:27:34

First Dose M/F: 08/26/08 / 08/26/08

Lab: SRI

Wistar Han RATS MALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
Adrenal Medulla	(49)	(48)	(50)	(49)
Infiltration Cellular, Eosinophil		1 (2%)		
Islets, Pancreatic	(49)	(49)	(50)	(50)
Hyperplasia	1 (2%)			1 (2%)
Parathyroid Gland	(47)	(49)	(50)	(50)
Cyst		2 (4%)		1 (2%)
Cyst, Multiple	1 (2%)			
Hyperplasia, Focal		1 (2%)	2 (4%)	
Pituitary Gland	(49)	(49)	(50)	(50)
Pars Distalis, Cyst	3 (6%)	3 (6%)	4 (8%)	4 (8%)
Pars Distalis, Cyst, Multiple	1 (2%)		1 (2%)	
Pars Distalis, Hyperplasia, Focal	15 (31%)	11 (22%)	13 (26%)	8 (16%)
Pars Intermedia, Cyst			1 (2%)	
Pars Intermedia, Hemorrhage	1 (2%)			
Pars Intermedia, Hyperplasia, Focal	2 (4%)		1 (2%)	
Pars Nervosa, Inflammation, Chronic	2 (4%)			2 (4%)
Thyroid Gland	(45)	(45)	(48)	(46)
Cyst	1 (2%)	1 (2%)		
Mineralization			1 (2%)	
C-cell, Hyperplasia	44 (98%)	41 (91%)	47 (98%)	44 (96%)
Follicle, Hypertrophy	1 (2%)	26 (58%)	34 (71%)	23 (50%)
Follicular Cell, Hyperplasia	8 (18%)	5 (11%)	5 (10%)	7 (15%)

GENERAL BODY SYSTEM

Tissue NOS	(3)	(3)	(2)	(1)
Fibrosis	1 (33%)		1 (50%)	1 (100%)
Inflammation, Chronic Active	1 (33%)			
Fat, Necrosis		1 (33%)		

GENITAL SYSTEM

Epididymis	(49)	(50)	(50)	(50)
Inflammation, Chronic				3 (6%)
Vacuolization Cytoplasmic	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 03

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Wistar Han

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 08/12/2014

Time Report Requested: 10:27:34

First Dose M/F: 08/26/08 / 08/26/08

Lab: SRI

Wistar Han RATS MALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
Bilateral, Granuloma Sperm		1 (2%)		
Preputial Gland	(49)	(49)	(50)	(50)
Inflammation, Granulomatous, Chronic	1 (2%)			
Inflammation, Chronic	3 (6%)	2 (4%)		2 (4%)
Inflammation, Chronic Active		4 (8%)	6 (12%)	2 (4%)
Mineralization	1 (2%)			
Duct, Ectasia	2 (4%)	2 (4%)	5 (10%)	15 (30%)
Prostate	(49)	(50)	(50)	(50)
Hyperplasia	1 (2%)			
Inflammation, Granulomatous	1 (2%)			
Inflammation, Chronic Active	17 (35%)	20 (40%)	28 (56%)	27 (54%)
Mineralization			1 (2%)	
Vacuolization Cytoplasmic Epithelium, Hyperplasia		1 (2%)		1 (2%)
Seminal Vesicle	(49)	(46)	(50)	(49)
Hyperplasia				1 (2%)
Inflammation, Acute	1 (2%)	1 (2%)		2 (4%)
Inflammation, Chronic Active		1 (2%)	1 (2%)	1 (2%)
Testes	(49)	(49)	(50)	(50)
Cyst				1 (2%)
Degeneration	14 (29%)	11 (22%)	12 (24%)	6 (12%)
Inflammation, Acute			1 (2%)	
Mineralization			1 (2%)	
Interstitial Cell, Hyperplasia, Focal			1 (2%)	
Interstitial Cell, Hyperplasia, Multifocal		1 (2%)		

HEMATOPOIETIC SYSTEM

Bone Marrow	(49)	(48)	(50)	(50)
Hyperplasia		1 (2%)		
Lymph Node	(2)	(6)	(5)	(6)
Ectasia		1 (17%)		
Mediastinal, Congestion		1 (17%)		
Mediastinal, Ectasia			2 (40%)	2 (33%)
Mediastinal, Hemorrhage	1 (50%)	2 (33%)	1 (20%)	2 (33%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 03

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Wistar Han

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 08/12/2014

Time Report Requested: 10:27:34

First Dose M/F: 08/26/08 / 08/26/08

Lab: SRI

Wistar Han RATS MALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
Mediastinal, Hyperplasia, Plasma Cell	1 (50%)			
Mediastinal, Pigmentation, Hemosiderin		1 (17%)	1 (20%)	1 (17%)
Pancreatic, Ectasia			1 (20%)	
Pancreatic, Inflammation, Chronic				1 (17%)
Renal, Ectasia		1 (17%)		
Lymph Node, Mandibular	(48)	(49)	(50)	(50)
Angiectasis		1 (2%)		
Ectasia	2 (4%)	7 (14%)	8 (16%)	7 (14%)
Hemorrhage	4 (8%)	1 (2%)	2 (4%)	1 (2%)
Hyperplasia, Plasma Cell			1 (2%)	
Pigmentation, Hemosiderin	1 (2%)			
Lymph Node, Mesenteric	(49)	(49)	(50)	(50)
Ectasia		2 (4%)	2 (4%)	1 (2%)
Hemorrhage	2 (4%)	1 (2%)	1 (2%)	4 (8%)
Pigmentation, Hemosiderin			2 (4%)	
Spleen	(47)	(46)	(50)	(49)
Accessory Spleen			1 (2%)	
Fibrosis, Focal	1 (2%)		1 (2%)	
Hematopoietic Cell Proliferation	23 (49%)	30 (65%)	22 (44%)	13 (27%)
Hemorrhage, Focal	1 (2%)			1 (2%)
Pigmentation	12 (26%)	11 (24%)	17 (34%)	27 (55%)
Lymphoid Follicle, Atrophy			1 (2%)	5 (10%)
Thymus	(45)	(49)	(49)	(50)
Atrophy	14 (31%)	11 (22%)	15 (31%)	26 (52%)
Ectopic Parathyroid Gland			3 (6%)	2 (4%)
Fibrosis				1 (2%)
Hemorrhage	1 (2%)	3 (6%)	1 (2%)	3 (6%)

INTEGUMENTARY SYSTEM

Mammary Gland	(33)	(38)	(39)	(41)
Cyst			1 (3%)	
Galactocele		1 (3%)		1 (2%)
Hyperplasia			3 (8%)	
Pigmentation, Hemosiderin	3 (9%)	9 (24%)	2 (5%)	13 (32%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 03
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/Wistar Han

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 08/12/2014
 Time Report Requested: 10:27:34
 First Dose M/F: 08/26/08 / 08/26/08
 Lab: SRI

Wistar Han RATS MALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
Duct, Dilatation	4 (12%)	1 (3%)	1 (3%)	1 (2%)
Skin	(49)	(49)	(50)	(50)
Cyst Epithelial Inclusion	1 (2%)	3 (6%)	1 (2%)	
Fibrosis		1 (2%)		
Hyperkeratosis		3 (6%)		
Inflammation, Granulomatous			1 (2%)	
Inflammation, Acute	1 (2%)	1 (2%)		
Inflammation, Chronic	1 (2%)			
Inflammation, Chronic Active	1 (2%)	3 (6%)		
Pigmentation				1 (2%)
Ulcer	1 (2%)	2 (4%)		
Epidermis, Hyperplasia		4 (8%)		

MUSCULOSKELETAL SYSTEM

Bone	(49)	(50)	(50)	(50)
Skeletal Muscle	(1)	(2)	(4)	(0)
Fibrosis			1 (25%)	
Inflammation, Chronic Active			1 (25%)	

NERVOUS SYSTEM

Brain	(49)	(50)	(50)	(50)
Compression	10 (20%)	9 (18%)	10 (20%)	26 (52%)
Meninges, Hyperplasia, Granulocytic			1 (2%)	
Peripheral Nerve	(2)	(1)	(3)	(0)
Spinal Cord	(2)	(1)	(3)	(0)

RESPIRATORY SYSTEM

Lung	(49)	(50)	(50)	(50)
Hemorrhage			1 (2%)	
Infiltration Cellular, Histiocyte	24 (49%)	24 (48%)	32 (64%)	30 (60%)
Inflammation, Granulomatous, Multifocal	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 03

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Wistar Han

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 08/12/2014

Time Report Requested: 10:27:34

First Dose M/F: 08/26/08 / 08/26/08

Lab: SRI

Wistar Han RATS MALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
Inflammation, Acute	2 (4%)	1 (2%)		1 (2%)
Inflammation, Chronic	4 (8%)			1 (2%)
Mineralization			2 (4%)	
Alveolar Epithelium, Hyperplasia	2 (4%)	3 (6%)	1 (2%)	5 (10%)
Artery, Mineralization				1 (2%)
Bronchus, Hyperplasia, Lymphoid				2 (4%)
Mediastinum, Inflammation, Granulomatous	1 (2%)			
Serosa, Fibrosis				1 (2%)
Vein, Mineralization		1 (2%)		
Nose	(49)	(49)	(50)	(50)
Fungus	2 (4%)		1 (2%)	1 (2%)
Inflammation, Acute	2 (4%)		2 (4%)	2 (4%)
Inflammation, Chronic Active			1 (2%)	1 (2%)
Ulcer, Multifocal				1 (2%)
Squamous Epithelium, Cyst	1 (2%)			
Trachea	(49)	(46)	(50)	(49)
Inflammation, Acute	1 (2%)			

SPECIAL SENSES SYSTEM

Eye	(46)	(46)	(50)	(45)
Retina, Atrophy	6 (13%)	8 (17%)	8 (16%)	3 (7%)
Harderian Gland	(49)	(49)	(50)	(50)
Atrophy			1 (2%)	
Hyperplasia, Focal	1 (2%)			
Lacrimal Gland	(0)	(0)	(1)	(2)
Inflammation, Chronic			1 (100%)	1 (50%)
Karyomegaly			1 (100%)	2 (100%)
Zymbal's Gland	(0)	(0)	(0)	(1)

URINARY SYSTEM

Kidney	(49)	(46)	(50)	(50)
Bacterium			1 (2%)	
Casts Protein				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 03

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Wistar Han

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 08/12/2014

Time Report Requested: 10:27:34

First Dose M/F: 08/26/08 / 08/26/08

Lab: SRI

Wistar Han RATS MALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
Cyst	1 (2%)		3 (6%)	
Cyst, Multiple			1 (2%)	
Hydronephrosis	1 (2%)	5 (11%)	8 (16%)	10 (20%)
Hyperplasia, Oncocytic				1 (2%)
Inflammation, Acute			1 (2%)	1 (2%)
Inflammation, Chronic				1 (2%)
Inflammation, Chronic Active	1 (2%)			
Nephropathy	37 (76%)	35 (76%)	32 (64%)	37 (74%)
Vacuolization Cytoplasmic				1 (2%)
Pelvis, Inflammation, Acute				1 (2%)
Pelvis, Inflammation, Chronic Active	22 (45%)	14 (30%)	8 (16%)	2 (4%)
Pelvis, Mineralization	18 (37%)	5 (11%)	5 (10%)	3 (6%)
Renal Tubule, Dilatation			1 (2%)	
Renal Tubule, Hyperplasia	1 (2%)			
Transitional Epithelium, Hyperplasia		1 (2%)		1 (2%)
Ureter	(1)	(0)	(0)	(0)
Cyst	1 (100%)			
Urinary Bladder	(49)	(48)	(50)	(50)
Calculus Gross Observation				1 (2%)
Inflammation, Chronic		1 (2%)		1 (2%)
Ulcer			1 (2%)	
Transitional Epithelium, Hyperplasia		1 (2%)	1 (2%)	1 (2%)

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 03
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/Wistar Han

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 08/12/2014
 Time Report Requested: 10:27:34
 First Dose M/F: 08/26/08 / 08/26/08
 Lab: SRI

Wistar Han RATS FEMALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
------------------------	---------	---------	----------	----------

Disposition Summary

Animals Initially In Study	60	50	50	60
Early Deaths				
Dosing Accident	2	1		
Moribund Sacrifice	8	10	13	11
Natural Death	3		4	10
Survivors				
Natural Death	1			
Terminal Sacrifice	36	39	33	28
Animals Examined Microscopically	50	50	50	49

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(49)
Hyperkeratosis	1 (2%)			
Inflammation, Chronic Active	1 (2%)			
Intestine Large, Cecum	(48)	(49)	(47)	(40)
Intestine Large, Colon	(48)	(49)	(50)	(46)
Intestine Large, Rectum	(49)	(49)	(49)	(45)
Degeneration, Fatty, Focal		1 (2%)		
Intestine Small, Duodenum	(47)	(49)	(47)	(42)
Epithelium, Vacuolization Cytoplasmic		1 (2%)		
Intestine Small, Ileum	(47)	(49)	(48)	(41)
Intestine Small, Jejunum	(46)	(49)	(47)	(42)
Liver	(50)	(49)	(50)	(47)
Angiectasis	1 (2%)		4 (8%)	2 (4%)
Basophilic Focus	2 (4%)	4 (8%)	7 (14%)	5 (11%)
Basophilic Focus, Multiple	42 (84%)	39 (80%)	33 (66%)	28 (60%)
Cholangiofibrosis				3 (6%)
Clear Cell Focus	2 (4%)	3 (6%)	1 (2%)	
Clear Cell Focus, Multiple	33 (66%)	18 (37%)	25 (50%)	31 (66%)
Congestion	3 (6%)			1 (2%)
Cyst			1 (2%)	
Eosinophilic Focus	5 (10%)	5 (10%)	10 (20%)	12 (26%)
Eosinophilic Focus, Multiple		2 (4%)	11 (22%)	19 (40%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 03

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Wistar Han

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 08/12/2014

Time Report Requested: 10:27:34

First Dose M/F: 08/26/08 / 08/26/08

Lab: SRI

Wistar Han RATS FEMALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
Fatty Change	15 (30%)	12 (24%)	28 (56%)	39 (83%)
Fibrosis			1 (2%)	
Hematopoietic Cell Proliferation	4 (8%)	1 (2%)		
Hepatodiaphragmatic Nodule	4 (8%)	5 (10%)		1 (2%)
Hyperplasia, Nodular			2 (4%)	7 (15%)
Inflammation, Granulomatous	1 (2%)			
Inflammation, Chronic	1 (2%)			
Mixed Cell Focus		1 (2%)		
Pigmentation	1 (2%)	2 (4%)	1 (2%)	
Bile Duct, Cyst	1 (2%)	2 (4%)	4 (8%)	6 (13%)
Bile Duct, Cyst, Multiple	1 (2%)		1 (2%)	1 (2%)
Bile Duct, Fibrosis	1 (2%)			
Bile Duct, Hyperplasia	16 (32%)	20 (41%)	16 (32%)	14 (30%)
Bile Duct, Inflammation, Chronic Active				1 (2%)
Hepatocyte, Degeneration			1 (2%)	
Hepatocyte, Hypertrophy		48 (98%)	49 (98%)	45 (96%)
Hepatocyte, Mitosis			1 (2%)	
Hepatocyte, Necrosis	4 (8%)	2 (4%)	1 (2%)	8 (17%)
Oval Cell, Hyperplasia	1 (2%)	3 (6%)	3 (6%)	10 (21%)
Serosa, Inflammation, Acute	1 (2%)			
Mesentery	(10)	(7)	(9)	(6)
Congestion	1 (10%)			
Inflammation, Granulomatous, Chronic Active		1 (14%)		
Inflammation, Chronic	1 (10%)			
Fat, Necrosis	8 (80%)	6 (86%)	5 (56%)	6 (100%)
Oral Mucosa	(0)	(0)	(1)	(1)
Pancreas	(50)	(49)	(49)	(47)
Atrophy	3 (6%)	3 (6%)	3 (6%)	5 (11%)
Inflammation, Granulomatous, Chronic		1 (2%)		
Inflammation, Chronic	3 (6%)		1 (2%)	
Salivary Glands	(50)	(50)	(49)	(45)
Cyst	1 (2%)			
Inflammation, Chronic	1 (2%)		1 (2%)	
Duct, Degeneration, Hyaline		1 (2%)		
Duct, Parotid Gland, Inflammation, Acute	1 (2%)	2 (4%)	4 (8%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 03

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Wistar Han

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 08/12/2014

Time Report Requested: 10:27:34

First Dose M/F: 08/26/08 / 08/26/08

Lab: SRI

Wistar Han RATS FEMALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
Duct, Submandibular Gland, Inflammation, Acute	1 (2%)			
Parotid Gland, Atrophy	4 (8%)	4 (8%)	4 (8%)	5 (11%)
Parotid Gland, Basophilic Focus				1 (2%)
Parotid Gland, Inflammation		1 (2%)		
Parotid Gland, Inflammation, Acute			1 (2%)	
Parotid Gland, Inflammation, Chronic	1 (2%)			
Parotid Gland, Necrosis				1 (2%)
Parotid Gland, Vacuolization Cytoplasmic	6 (12%)	9 (18%)	7 (14%)	2 (4%)
Sublingual Gland, Ectopic Tissue			1 (2%)	1 (2%)
Sublingual Gland, Vacuolization Cytoplasmic		1 (2%)		
Submandibular Gland, Ectopic Tissue				1 (2%)
Submandibular Gland, Inflammation, Acute		1 (2%)		
Submandibular Gland, Inflammation, Chronic				1 (2%)
Submandibular Gland, Necrosis		1 (2%)		
Stomach, Forestomach	(50)	(49)	(50)	(48)
Edema	1 (2%)	1 (2%)	2 (4%)	
Foreign Body	1 (2%)			
Hyperkeratosis	4 (8%)	6 (12%)	7 (14%)	4 (8%)
Inflammation, Acute		3 (6%)	1 (2%)	
Inflammation, Chronic	1 (2%)		3 (6%)	2 (4%)
Inflammation, Chronic Active	2 (4%)	2 (4%)	2 (4%)	1 (2%)
Mineralization		2 (4%)	3 (6%)	1 (2%)
Ulcer	2 (4%)	4 (8%)	3 (6%)	3 (6%)
Epithelium, Hyperplasia	5 (10%)	6 (12%)	6 (12%)	4 (8%)
Stomach, Glandular	(49)	(49)	(50)	(46)
Erosion			1 (2%)	
Inflammation, Acute		1 (2%)	2 (4%)	
Inflammation, Chronic				1 (2%)
Mineralization	9 (18%)	11 (22%)	14 (28%)	7 (15%)
Necrosis			1 (2%)	
Ulcer		1 (2%)	1 (2%)	1 (2%)
Tooth	(1)	(0)	(0)	(0)
Inflammation, Chronic	1 (100%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 03

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Wistar Han

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 08/12/2014

Time Report Requested: 10:27:34

First Dose M/F: 08/26/08 / 08/26/08

Lab: SRI

Wistar Han RATS FEMALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
CARDIOVASCULAR SYSTEM				
Blood Vessel	(1)	(0)	(3)	(3)
Inflammation, Acute	1 (100%)			
Heart	(50)	(50)	(50)	(48)
Cardiomyopathy	12 (24%)	8 (16%)	10 (20%)	4 (8%)
Inflammation, Chronic	1 (2%)			
Epicardium, Inflammation, Chronic		1 (2%)		
Epicardium, Inflammation, Chronic Active	1 (2%)			
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(49)	(50)	(46)
Accessory Adrenal Cortical Nodule, Multifocal		1 (2%)		
Angiectasis	45 (90%)	44 (90%)	44 (88%)	34 (74%)
Hematopoietic Cell Proliferation	1 (2%)		3 (6%)	1 (2%)
Hemorrhage	1 (2%)			
Hyperplasia, Focal	8 (16%)	6 (12%)	12 (24%)	19 (41%)
Hypertrophy, Focal	13 (26%)	9 (18%)	12 (24%)	14 (30%)
Necrosis		1 (2%)		
Vacuolization Cytoplasmic	5 (10%)	5 (10%)	7 (14%)	9 (20%)
Adrenal Medulla	(50)	(50)	(50)	(47)
Hyperplasia, Focal			1 (2%)	
Islets, Pancreatic	(50)	(49)	(49)	(47)
Hyperplasia	1 (2%)			
Hypertrophy	1 (2%)			
Pigmentation, Hemosiderin	1 (2%)			
Parathyroid Gland	(49)	(47)	(49)	(46)
Pituitary Gland	(50)	(49)	(50)	(47)
Pigmentation, Hemosiderin			2 (4%)	
Pars Distalis, Cyst	3 (6%)			1 (2%)
Pars Distalis, Cyst, Multiple		1 (2%)	3 (6%)	
Pars Distalis, Hyperplasia, Focal	14 (28%)	9 (18%)	17 (34%)	9 (19%)
Pars Distalis, Vacuolization Cytoplasmic				1 (2%)
Pars Intermedia, Hyperplasia, Focal		1 (2%)		1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 03

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Wistar Han

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 08/12/2014

Time Report Requested: 10:27:34

First Dose M/F: 08/26/08 / 08/26/08

Lab: SRI

Wistar Han RATS FEMALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
Pars Intermedia, Hypertrophy		1 (2%)		
Pars Nervosa, Cyst, Multiple			1 (2%)	
Pars Nervosa, Inflammation, Chronic	1 (2%)		1 (2%)	1 (2%)
Thyroid Gland	(45)	(49)	(47)	(42)
Mineralization				1 (2%)
C-cell, Hyperplasia	45 (100%)	48 (98%)	46 (98%)	38 (90%)
Follicle, Cyst	2 (4%)		2 (4%)	
Follicle, Cyst, Multiple	1 (2%)			
Follicle, Hypertrophy	8 (18%)	17 (35%)	22 (47%)	35 (83%)
Follicular Cell, Hyperplasia	1 (2%)	5 (10%)	4 (9%)	6 (14%)
Follicular Cell, Hypertrophy			1 (2%)	

GENERAL BODY SYSTEM

Tissue NOS	(3)	(2)	(4)	(2)
Abscess	1 (33%)			
Fibrosis			1 (25%)	1 (50%)
Inflammation, Suppurative, Chronic Active		1 (50%)		
Inflammation, Acute	1 (33%)			
Inflammation, Chronic Active	1 (33%)			

GENITAL SYSTEM

Clitoral Gland	(49)	(49)	(50)	(47)
Inflammation, Chronic	1 (2%)	1 (2%)	1 (2%)	
Inflammation, Chronic Active			1 (2%)	2 (4%)
Duct, Cyst	2 (4%)	4 (8%)	3 (6%)	3 (6%)
Duct, Cyst, Multiple		1 (2%)		
Ovary	(50)	(49)	(50)	(46)
Atrophy	1 (2%)	3 (6%)	1 (2%)	2 (4%)
Cyst	5 (10%)	5 (10%)	8 (16%)	8 (17%)
Cyst, Multiple			1 (2%)	
Hyperplasia, Tubulostromal		4 (8%)	3 (6%)	1 (2%)
Follicle, Cyst	4 (8%)	2 (4%)	3 (6%)	5 (11%)
Follicle, Cyst, Multiple	2 (4%)	1 (2%)		1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 03

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Wistar Han

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 08/12/2014

Time Report Requested: 10:27:34

First Dose M/F: 08/26/08 / 08/26/08

Lab: SRI

Wistar Han RATS FEMALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
Granulosa Cell, Hyperplasia, Multifocal				1 (2%)
Uterus	(50)	(49)	(50)	(47)
Adenomyosis		1 (2%)		
Angiectasis	1 (2%)			
Cyst		1 (2%)		
Cyst, Squamous				1 (2%)
Decidual Reaction			1 (2%)	1 (2%)
Dilatation			1 (2%)	1 (2%)
Hemorrhage	1 (2%)		1 (2%)	
Hyperplasia, Atypical	3 (6%)	1 (2%)	2 (4%)	
Inflammation, Chronic	1 (2%)			
Inflammation, Chronic Active		1 (2%)		
Metaplasia, Squamous			1 (2%)	4 (9%)
Cervix, Hyperkeratosis			1 (2%)	
Cervix, Hyperplasia, Squamous				2 (4%)
Endometrium, Hyperplasia, Cystic	15 (30%)	9 (18%)	17 (34%)	14 (30%)
Myometrium, Degeneration, Mucoid			1 (2%)	
Serosa, Cyst			1 (2%)	
Serosa, Inflammation, Acute	1 (2%)			
Vagina	(1)	(1)	(2)	(2)

HEMATOPOIETIC SYSTEM

Bone Marrow	(50)	(50)	(50)	(46)
Fibrosis				1 (2%)
Myeloid Cell, Hyperplasia	6 (12%)	4 (8%)	7 (14%)	11 (24%)
Lymph Node	(10)	(5)	(6)	(9)
Pigmentation, Hemosiderin	1 (10%)			
Axillary, Ectasia	1 (10%)			
Axillary, Hyperplasia, Lymphoid	1 (10%)			
Axillary, Pigmentation	1 (10%)			
Iliac, Hyperplasia, Lymphoid				1 (11%)
Inguinal, Pigmentation	2 (20%)		2 (33%)	
Mediastinal, Ectasia		1 (20%)	1 (17%)	
Mediastinal, Hemorrhage	2 (20%)	1 (20%)		1 (11%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 03

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Wistar Han

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 08/12/2014

Time Report Requested: 10:27:34

First Dose M/F: 08/26/08 / 08/26/08

Lab: SRI

Wistar Han RATS FEMALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
Mediastinal, Hyperplasia, Lymphoid				1 (11%)
Mediastinal, Hyperplasia, Plasma Cell			1 (17%)	
Mediastinal, Inflammation, Granulomatous, Chronic Active		1 (20%)		
Mediastinal, Pigmentation			1 (17%)	
Mediastinal, Pigmentation, Hemosiderin	3 (30%)	2 (40%)	1 (17%)	4 (44%)
Pancreatic, Hemorrhage	1 (10%)			
Pancreatic, Pigmentation, Hemosiderin	1 (10%)			1 (11%)
Popliteal, Hemorrhage				1 (11%)
Popliteal, Hyperplasia, Lymphoid				1 (11%)
Popliteal, Pigmentation		1 (20%)		3 (33%)
Lymph Node, Mandibular	(50)	(50)	(50)	(48)
Ectasia	4 (8%)	2 (4%)	4 (8%)	1 (2%)
Hemorrhage	2 (4%)			
Hyperplasia, Lymphoid				2 (4%)
Hyperplasia, Plasma Cell				1 (2%)
Necrosis	1 (2%)			
Pigmentation, Hemosiderin		1 (2%)		
Lymph Node, Mesenteric	(50)	(49)	(50)	(46)
Ectasia	2 (4%)	1 (2%)	2 (4%)	1 (2%)
Hemorrhage	1 (2%)	4 (8%)	3 (6%)	1 (2%)
Hyperplasia, Lymphoid	1 (2%)			
Infiltration Cellular, Histiocyte	1 (2%)			
Inflammation, Acute	1 (2%)			
Pigmentation, Hemosiderin	1 (2%)	1 (2%)	1 (2%)	
Spleen	(50)	(49)	(50)	(45)
Accessory Spleen	1 (2%)	1 (2%)		
Angiectasis				1 (2%)
Hematopoietic Cell Proliferation	27 (54%)	24 (49%)	19 (38%)	17 (38%)
Hemorrhage		1 (2%)	1 (2%)	
Pigmentation	31 (62%)	31 (63%)	32 (64%)	27 (60%)
Capsule, Fibrosis, Focal	1 (2%)			
Lymphoid Follicle, Atrophy		2 (4%)	3 (6%)	1 (2%)
Thymus	(50)	(49)	(48)	(46)
Atrophy	10 (20%)	7 (14%)	18 (38%)	9 (20%)
Cyst				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 03
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/Wistar Han

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 08/12/2014
 Time Report Requested: 10:27:34
 First Dose M/F: 08/26/08 / 08/26/08
 Lab: SRI

Wistar Han RATS FEMALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
Hemorrhage	4 (8%)	6 (12%)	5 (10%)	1 (2%)

INTEGUMENTARY SYSTEM

Mammary Gland	(50)	(49)	(50)	(48)
Degeneration, Fatty	1 (2%)			
Fibrosis			2 (4%)	
Galactocele	2 (4%)		3 (6%)	3 (6%)
Hyperplasia	26 (52%)	28 (57%)	24 (48%)	19 (40%)
Inflammation, Granulomatous			1 (2%)	
Inflammation, Chronic Active				1 (2%)
Duct, Cyst	1 (2%)		1 (2%)	
Duct, Dilatation	16 (32%)	19 (39%)	13 (26%)	6 (13%)
Duct, Inflammation, Acute				1 (2%)
Skin	(50)	(50)	(50)	(49)
Fibrosis	1 (2%)			
Hyperkeratosis	1 (2%)		2 (4%)	
Inflammation, Acute			2 (4%)	
Inflammation, Chronic		1 (2%)	1 (2%)	
Inflammation, Chronic Active		1 (2%)		1 (2%)
Ulcer	1 (2%)		2 (4%)	1 (2%)
Epidermis, Hyperplasia		1 (2%)	1 (2%)	2 (4%)

MUSCULOSKELETAL SYSTEM

Bone	(50)	(50)	(50)	(49)
Skeletal Muscle	(1)	(0)	(0)	(0)

NERVOUS SYSTEM

Brain	(50)	(50)	(50)	(49)
Compression	8 (16%)	9 (18%)	11 (22%)	13 (27%)
Cyst	1 (2%)			
Hemorrhage, Multifocal			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 03
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: RATS/Wistar Han

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 08/12/2014
 Time Report Requested: 10:27:34
 First Dose M/F: 08/26/08 / 08/26/08
 Lab: SRI

Wistar Han RATS FEMALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
Peripheral Nerve	(0)	(0)	(1)	(0)
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(49)
Infiltration Cellular, Histiocyte	25 (50%)	23 (46%)	22 (44%)	30 (61%)
Inflammation, Acute				1 (2%)
Inflammation, Chronic	1 (2%)			1 (2%)
Mineralization			1 (2%)	1 (2%)
Alveolar Epithelium, Hyperplasia	1 (2%)	3 (6%)	1 (2%)	
Serosa, Inflammation, Acute	1 (2%)			
Nose	(50)	(50)	(50)	(47)
Inflammation, Acute		1 (2%)	1 (2%)	1 (2%)
Trachea	(47)	(50)	(50)	(47)
Inflammation, Chronic		1 (2%)	1 (2%)	
SPECIAL SENSES SYSTEM				
Ear	(1)	(0)	(0)	(0)
Eye	(50)	(49)	(47)	(45)
Developmental Malformation		1 (2%)		
Mineralization	1 (2%)			
Retina, Atrophy	9 (18%)	3 (6%)	9 (19%)	10 (22%)
Harderian Gland	(49)	(50)	(50)	(49)
URINARY SYSTEM				
Kidney	(50)	(50)	(49)	(47)
Calculus Gross Observation	1 (2%)			
Casts Protein	2 (4%)			2 (4%)
Cyst	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Cyst, Multiple	1 (2%)			1 (2%)
Hydronephrosis	1 (2%)	1 (2%)	1 (2%)	6 (13%)
Inflammation, Chronic	2 (4%)		1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20209 - 03

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/Wistar Han

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 08/12/2014

Time Report Requested: 10:27:34

First Dose M/F: 08/26/08 / 08/26/08

Lab: SRI

Wistar Han RATS FEMALE	0 MG/KG	3 MG/KG	15 MG/KG	50 MG/KG
Inflammation, Chronic Active			1 (2%)	
Nephropathy	13 (26%)	8 (16%)	17 (35%)	15 (32%)
Pigmentation		1 (2%)	3 (6%)	4 (9%)
Pelvis, Inflammation, Acute	1 (2%)			
Pelvis, Inflammation, Chronic Active	16 (32%)	10 (20%)	6 (12%)	3 (6%)
Pelvis, Mineralization	31 (62%)	29 (58%)	23 (47%)	19 (40%)
Renal Tubule, Dilatation			1 (2%)	
Transitional Epithelium, Hyperplasia	3 (6%)	4 (8%)	1 (2%)	2 (4%)
Ureter	(1)	(0)	(0)	(1)
Inflammation, Chronic				1 (100%)
Mineralization				1 (100%)
Transitional Epithelium, Hyperplasia	1 (100%)			
Urinary Bladder	(50)	(49)	(49)	(45)
Inflammation, Chronic				1 (2%)
Inflammation, Chronic Active	1 (2%)			
Transitional Epithelium, Hyperplasia	1 (2%)			

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion